{"id":"bc-007","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":{"chemblId":"CHEMBL5974311","moleculeType":null,"molecularWeight":"379.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BC 007 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.","oneSentence":"BC 007 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:22.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05911009","phase":"PHASE2","title":"To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID","status":"COMPLETED","sponsor":"Berlin Cures GmbH","startDate":"2023-06-16","conditions":"Long Covid","enrollment":119},{"nctId":"NCT04192214","phase":"PHASE2","title":"The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor","status":"COMPLETED","sponsor":"Berlin Cures GmbH","startDate":"2019-03-29","conditions":"Cardiomyopathy, Dilated, Heart Failure, Autoantibodies","enrollment":30},{"nctId":"NCT02955420","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects","status":"COMPLETED","sponsor":"Berlin Cures GmbH","startDate":"2016-08","conditions":"Healthy Volunteers","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BC 007","genericName":"BC 007","companyName":"Berlin Cures GmbH","companyId":"berlin-cures-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BC 007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}